CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 4 enrolled
Drug / intervention
OnabotulinumtoxinA (Botox®) Injections +2 moredrug
Likely dose
OnabotulinumtoxinA (Botox®) Injections 64 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06778421
NCT06778421Phase 1Completed

Pilot Study to Identify the Impact of OnabotulinumtoxinA (BOTOX®) on Patient Perceived Stress.

Center for Advanced Facial Plastic Surgery·interventional·Posted Jan 16, 2025·Updated Apr 29, 2026

In Brief

A Phase 1 clinical trial evaluating Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, and 1 other intervention for Stress (Psychology) and 8 related conditions. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The purpose of this prospective single-center, blinded\*, randomized, proof-of-concept study is to determine whether OnabotulinumtoxinA (BOTOX®) injections will change the level of stress perceived by generally healthy adult female participants. It is hypothesized that BOTOX® injections will be associated with decreases in perceived stress levels, measured by scores on the Perceived Stress Scale (PSS) questionnaire. The primary outcome measure is a chronological decrease in PSS scores between any two points of the study period. Comparison of the placebo- and BOTOX®-treated participant scores will either support or disprove the study hypothesis. Qualified participants who meet the study requirements, including a one-time completion of basic laboratory testing before treatment. The treatment visit starts on day-1 of a 12-week period, which consists a total of four clinic visits and one online visit, which involve: * vital signs and Body Mass Index (BMI) measurements * basic/interval history and physical * 2 Perceived Stress Scale (PSS) questionnaires * injection of 64 units of either BOTOX® or sterile salt solution * stay for 60-minutes after treatment for monitoring and to complete study tasks

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedJan 16, 2025
Enrollment StartMar 19, 2025
Primary CompletionSep 10, 2025
Study CompletionJan 10, 2026
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 1.5 years ago

Interventions

Intramuscular injectionprocedure

Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents

OnabotulinumtoxinA (Botox®) Injectionsdrug

Injection of 64 units of active drug at a ratio of 4 units to 0.1 mL of sterile, preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only \- Abbvie/Allergan drug.

Sodium Chlorideother

Placebo injection of the same volume of preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only.